文献速递造血干细胞移植与细胞治疗血栓与止血

人工智能解读心电图图像预测造血干细胞移植毒性

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性研究纳入1377例造血干细胞移植患者(自体849例,异基因528例),将移植前心电图交由外部训练的深度学习模型预测心房颤动风险。移植前AI-ECG预测的房颤风险与临床房颤发生(HR 7.37)、较差生存(HR 2.4)和非复发死亡(HR 3.36)相关,且与死亡关联仅见于异基因移植者。移植后使用环磷酰胺者90天房颤发生率高于钙调神经磷酸酶抑制剂方案(13% vs 5%)。

要点

  • 移植前AI-ECG预测的房颤风险与移植后临床房颤、生存和非复发死亡相关。
  • AI-ECG预测风险与死亡关联仅见于异基因移植受者。
  • 移植后使用环磷酰胺者90天房颤发生率13% vs 钙调神经磷酸酶抑制剂方案5%。

核心结论

  • AI-ECG可提供造血干细胞移植患者移植后心脏结局和生存的风险信息,代表一种个性化风险评估的新策略。

研究设计与样本

  • 回顾性研究,将移植前获取的心电图交由外部训练的深度学习模型(设计用于预测房颤风险)进行解读。
  • 共纳入1377例患者,其中自体造血干细胞移植849例,异基因造血干细胞移植528例。
  • 中位随访2.9年。

主要发现

  • 自体移植者3年房颤累积发生率为9%(95%CI 7-12),异基因移植者为13%(95%CI 10-16)。
  • 在全队列中,移植前AI-ECG房颤风险估计与临床房颤发生高度相关(HR 7.37;95%CI 3.53-15.4;P<.001)。
  • 移植前AI-ECG房颤风险估计与较差生存相关(HR 2.4;95%CI 1.3-4.5;P=.004),与非复发死亡风险较高相关(HR 3.36;95%CI 1.39-8.13;P=.007),未增加复发风险。
  • 与死亡的相关性仅在异基因移植受者中观察到,其中非复发死亡风险更高。
  • 移植后使用环磷酰胺者90天房颤发生率高于钙调神经磷酸酶抑制剂为基础的移植物抗宿主病预防方案(13% vs 5%;P=.01),与移植后AI-ECG房颤预测的时间变化相对应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Artificial intelligence (AI)-enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the risk of cardiac complications and mortality in patients undergoing hematopoietic cell transplantation (HCT). We retrospectively subjected ECGs obtained before HCT to an externally trained, deep-learning model designed to predict the risk of atrial fibrillation (AF). Included were 1377 patients (849 autologous [auto] HCT and 528 allogeneic [allo] HCT recipients). The median follow-up was 2.9 years. The 3-year cumulative incidence of AF was 9% (95% confidence interval [CI], 7-12) in patients who underwent auto HCT and 13% (10%-16%) in patients who underwent allo HCT. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with the development of clinical AF (hazard ratio [HR], 7.37; 95% CI, 3.53-15.4; P < .001), inferior survival (HR, 2.4; 95% CI, 1.3-4.5; P = .004), and greater risk of nonrelapse mortality (NRM; HR, 95% CI, 3.36; 1.39-8.13; P = .007), without increased risk of relapse. Association with mortality was only noted in allo HCT recipients, where the risk of NRM was greater. The use of cyclophosphamide after transplantation resulted in greater 90-day incidence of AF (13% vs 5%; P = .01) compared to calcineurin inhibitor-based graft-versus-host disease prophylaxis, corresponding to temporal changes in AI-ECG AF prediction after HCT. In summary, AI-ECG can inform risk of posttransplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shaffer BC, Brown S, Chinapen S, et al. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity. Blood Adv. 2024. PMID: 39158065. doi:10.1182/bloodadvances.2024013636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。